Change - Announcement of Appointment::Appointment of Independent and Non-Executive Director

Issuer & Securities

Issuer/ Manager
ACCRELIST LTD.
Securities
ACCRELIST LTD - SGXE69448095 - QZG
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
30-Oct-2024 22:07:37
Status
New
Announcement Sub Title
Appointment of Independent and Non-Executive Director
Announcement Reference
SG241030OTHRGHAI
Submitted By (Co./ Ind. Name)
Dr. Terence Tea Yeok Kian
Designation
Executive Chairman and Managing Director
Description (Please provide a detailed description of the event in the box below)
Appointment of Dr. Tan Tze Sheng, Edwin (Chen Zhisheng, Edwin) ("Dr. Tan") as an Independent and Non-Executive Director

This announcement has been reviewed by the Company's sponsor, RHT Capital Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the sponsor is Mr. Joseph Au at 36 Robinson Road, #10-06 City House, Singapore 068877, Email: sponsor@rhtgoc.com.

Additional Details

Date Of Appointment
30/10/2024
Name Of Person
Dr. Tan Tze Sheng, Edwin (Chen Zhisheng, Edwin)
Age
44
Country Of Principal Residence
Singapore
The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process)
The Board of Directors, having considered the recommendation of the Nominating Committee and having assessed Dr. Tan's qualifications, experience and suitability, is of the view that he has the requisite experience and capabilities to assume the duties and responsibilities as an Independent and Non-Executive Director of the Company. Dr. Tan will also be appointed as a member of the Audit Committee and Remuneration Committee of the Company.

The Board of Directors considers Dr. Tan to be independent for the purpose of Rule 704(7) of the Catalist Rules.
Whether appointment is executive, and if so, the area of responsibility
Non-Executive
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Independent and Non-Executive Director, member of the Audit Committee and Remuneration Committee.
Professional qualifications
1. Registered Medical Specialist at Singapore Medical Council
2. Bachelor of Medicine and Bachelor of Surgery at National University of Singapore
3. Member at Royal College of Surgeons
4. Master of Medicine (Orthopaedic Surgery) at National University of Singapore
5. Fellowship at the Royal College of Surgeons
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
Nil
Conflict of interests (including any competing business)
Livingstone Health Consolidated Pte. Ltd. ("LHCPL") is a substantial shareholder of Livingstone Health Holdings Limited ("LHHL") holding 215,311,056 shares representing 43.77% equity interest in LHHL. Dr. Tan is deemed to have an interest in the 215,311,056 shares in the capital of LHHL which is held by LHCPL by virtue of him being a shareholder in LHCPL. In addition, Dr. Tan also has a direct interest in 24,118,400 shares in the capital of LHHL.

LHHL operates in the same general industry as the Company and its subsidiaries. However, LHHL is not a direct competitor of the Company and its subsidiaries as it provides different products and services as compared to the Company and its subsidiaries.

Should any conflict of interest arise of which Dr. Tan is aware in respect of himself, Dr. Tan will make such conflict known to the Board as soon as he is aware so that he may recuse himself from such related discussions and/or decisions and resolutions as most appropriate. Further, any future transactions between the Company or its subsidiaries and any company where Dr. Tan is a director of or has substantial interest in will be done on an arms-length basis, normal commercial terms and not prejudicial to the interest of the Company and its minority shareholders. The Nominating Committee further notes that Dr. Tan is not involved in the management or business operations of LHHL.

In view of the above, the Nominating Committee and the Board are satisfied with the appointment of Dr. Tan as an Independent and Non-Executive Director of the Company.
Working experience and occupation(s) during the past 10 years
1. May 2023 - Present: Medical Doctor (Orthopaedic Surgery) at Auspicium Medical Pte. Ltd.
2. January 2020 - May 2023: Medical Doctor (Orthopaedic Surgery) at Livingstone Health Holdings Limited
3. December 2018 - December 2019: Medical Doctor (Orthopaedic Surgery) at Ardmore Sports & Reconstruction (SN Orthopaedics Pte. Ltd.)
4. May 2014 - December 2018: Medical Doctor (Orthopaedic Surgery) at Singapore General Hospital
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
No
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
Directorships:
1. Autoswift Recovery Pte Ltd
2. Cove Sports & Reconstruction Pte Ltd
3. Seven8 Pte Ltd
4. The Bone & Joint Centre Pte Ltd
5. Precision Medical Services Pte Ltd
6. Auspicium Investments Pte Ltd
7. Quantum Orthopaedics Pte. Ltd.
Present
Directorships:
1. Auspicium Medical Pte.
Ltd.
2. AAS Insurance Agency Pte Ltd
3. AAS Academy Pte Ltd
4. AAS @2KC Pte Ltd
5. Invictus Sports Pte Ltd
6. Joint Ease Pte Ltd
7. ARE Clinic Pte Ltd


Principal Commitments: Specialist Orthopaedic Surgeon in Auspicium Orthopaedic Centre
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
Yes
If Yes, Please provide full details
Dr. Tan received a notice of complaint from the Singapore Medical Council ("SMC") dated 4 July 2019. In the complaint, an allegation was made by a patient against Dr. Tan for medical negligence due to two pieces of retained gauze left in the patient's wound after a procedure involving an incision and drainage of the calf abscess (the "Procedure") in 2018 (the "Complaint"). The patient alleged that the surgeon in charge was Dr. Tan, and had requested for SMC to investigate on this matter.

Following an investigation conducted by the Complaints Committee of the SMC, the SMC issued a conclusion of inquiry to Dr. Tan on 23 June 2020, informing that the Complaint had been dismissed because the allegations founding the Complaint were misconceived as Dr. Tan had not been directly involved in the Procedure. To the best of Dr. Tan's knowledge and belief, no action has been taken against him and there have not been any further developments on this matter.
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
Pursuant to Rule 406(3)(a) of the Catalist Rules, the Company will arrange for Dr. Tan to attend the relevant training on the roles and responsibilities of a director of a listed issuer in Singapore as prescribed by the Exchange under Practice Note 4D of the Catalist Rules within one year from the date of his appointment to the Board.